Healthy Volunteers Clinical Trial
Official title:
Phase I Randomized Clinical Trial of Evaluation of Zolpidem Hemitartarate Pharmacokinetics (Orodispersible Tablet 1.75 mg and 3.50 mg) After Single Dose Oral Administration in Male and Female Healthy Subjects
NCT number | NCT02607696 |
Other study ID # | GDN 057/15 |
Secondary ID | |
Status | Withdrawn |
Phase | Phase 1 |
First received | November 16, 2015 |
Last updated | January 31, 2017 |
Start date | May 2016 |
Verified date | January 2017 |
Source | Biolab Sanus Farmaceutica |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a Phase I, open-label, randomized trial to evaluate the single-dose pharmacokinetics
of Zolpidem orodispersible tablet at two different dosages (1.75 mg and 3.50 mg). Sample
size is 48 participants, male or female, aged above 18 years-old.
Primary objective is to evaluate pharmacokinetics of Zolpidem orodispersible tablet at two
different dosages (1.75 mg and 3.50 mg), and secondary objective is to evaluate safety and
tolerability of the investigational product.
Participants will be admitted for a period of 36 hours, when investigational product will be
administered, and blood samples, at pre-determined time periods, will be collected for
pharmacokinetics.
Primary endpoint is to obtain pharmacokinetics parameters. Additionally, safety will be
assessed by adverse events occurrence and laboratory exams evaluation.
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | |
Est. primary completion date | October 2016 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Male or female study participants, aged above 18 years-old; women cannot be pregnant or breastfeeding - Body mass index (BMI) greater than or equal to 19 and less than or equal to 28.75 Kg/m2 - Good health conditions or without significant diseases, according to best medical judgement, according to protocol requirements and study evaluations: medical history, blood pressure and heart rate measurements, physical examination, electrocardiogram (ECG) and complementary laboratory tests - Ability to understand the nature and objectives of the trial, including risks and adverse events; willingness to cooperate with the researcher and proceed according to all study requirements, which shall be confirmed by Informed Consent Form signature. Exclusion Criteria: - Known hypersensitivity to the investigational product (Zolpidem) or chemically related compounds; history of serious adverse reactions or hypersensitivity to any drug - History or presence of hepatic or gastrointestinal diseases, or other condition that interferes with drug absorption, distribution, excretion or metabolism - Chronic therapy with any drugs, except oral contraceptives - History of hepatic, kidney, lungs, gastrointestinal, epileptic, hematologic or psychiatric disease; hypotension or hypertension, of any etiology, that requires pharmacological treatment; history of myocardial infarction, angina and/or heart failure - Electrocardiographic findings that, at investigator criteria, are not recommended for study participation - Deviations on screening laboratory results that are considered as clinically relevant by the researcher - Smoking - Intake of more that 5 cups of coffee or tea per day - Unusual food habits, e.g., vegetarians - History of drugs and alcohol addiction or excessive alcohol consumption (> 35 g/day) - Use of regular medications within 2 weeks prior study enrollment or use of any medications within one week prior to study enrollment, except oral contraceptives or cases which, based on drug's or metabolite's half-life, complete elimination can be assumed - Hospitalization for any reasons up to 8 weeks before trial - Treatment, within 6 months before the trial, with any drugs with known and well-established toxic potential to major organs - Participation in any other experimental research or administration of any experimental drug within 6 months before this trial - Donation or loss of 450 mL or more of blood within 3 months before this trial or 3 donations (women)/4 donations (men) of blood within 12 months before this trial - Any condition, according to investigator's best judgement, that prevents the subject to participate in the trial - Pregnancy, labor or miscarriage with 12 weeks before admission predicted date. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Biolab Sanus Farmaceutica |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Area under the curve(0-last) | 24 hours | ||
Primary | Area under the curve(0-all) | 24 hours | ||
Primary | Area under the curve(0-inf) | 24 hours | ||
Primary | Half-life (t1/2) | 24 hours | ||
Primary | Elimination rate constant (Ke) | 24 hours | ||
Primary | Maximum serum concentration (Cmax) | 24 hours | ||
Primary | Time to reach maximum (peak) plasma concentration following drug administration (tmax) | 24 hours | ||
Primary | Time of the last measurable (positive) concentration (tlast) | 24 hours | ||
Primary | Area under the first moment of the plasma concentration-time curve extrapolated from time zero to infinity as a percentage of total AUC | 24 hours | ||
Secondary | Number of adverse events | 60 days | ||
Secondary | Intensity of adverse events | 60 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05001152 -
Taste Assessment of Ozanimod
|
Phase 1 | |
Completed |
NCT05029518 -
3-Way Crossover Study to Compare the PK (Pharmokinetics) and to Evaluate the Effect of Food on the Bioavailability
|
Phase 1 | |
Completed |
NCT04493255 -
A Study to Determine the Metabolism and Elimination of [14C]E7090 in Healthy Male Participants
|
Phase 1 | |
Completed |
NCT03457649 -
IV Dose Study to Assess the Safety, Tolerability, PK, PD and Immunogenicity of ARGX-113 in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT00995891 -
Collection of Blood, Bone Marrow, and Buccal Mucosa Samples From Healthy Volunteers for Center for Human Immunology, Autoimmunity, and Inflammatory Diseases (CHI) Laboratory Research Studies
|
||
Completed |
NCT05043766 -
Evaluation of Oral PF614 Relative to OxyContin
|
Phase 1 | |
Completed |
NCT05050318 -
Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively
|
Phase 4 | |
Completed |
NCT04466748 -
A Multiple Ascending Dose Pharmacology Study of Anaprazole in Healthy Chinese Subjects
|
Phase 1 | |
Completed |
NCT00746733 -
Vyvanse and Adderall XR Given Alone and in Combination With Prilosec OTC
|
Phase 1 | |
Recruiting |
NCT05929651 -
Study of Immunogenicity and Safety of MenQuadfi® as a Booster Vaccine in Toddlers 12 to 23 Months, Regardless of the Quadrivalent Meningococcal Conjugate Vaccine Used for Priming in Infancy
|
Phase 4 | |
Completed |
NCT05954039 -
Evaluation of the Efficacy of a Dietary Supplement on Hair Loss and Hair Aspect
|
N/A | |
Completed |
NCT05045716 -
A Study of Subcutaneous Lecanemab in Healthy Participants
|
Phase 1 | |
Active, not recruiting |
NCT02747927 -
Efficacy, Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children
|
Phase 3 | |
Completed |
NCT05533801 -
A Study to Demonstrate the Bioequivalence of Lecanemab Supplied in Vials and a Single-Use Auto-Injector (AI) in Healthy Participants
|
Phase 1 | |
Not yet recruiting |
NCT03931369 -
Adaptation of Thirst to a Single Administration of Tolvaptan (TOLVATHIRST)
|
Phase 2 | |
Completed |
NCT03279146 -
A Single Dose Study Evaluating PK of TXL Oral Formulations in Healthy Subjects
|
Phase 1 | |
Completed |
NCT06027437 -
A Study to Assess the Relative Biological Availability and the Effect of Food on the Drug Levels of Danicamtiv in Healthy Adult Participants
|
Phase 1 | |
Recruiting |
NCT05619874 -
Effects of Two Virtual HIFCT Programs in Adults With Abdominal Obesity
|
N/A | |
Completed |
NCT05553418 -
Investigational On-body Injector Clinical Study
|
N/A | |
Completed |
NCT04092712 -
Study Evaluating Pharmacokinetics and Mass Balance of [14C]-CTP-543 in Healthy Adult Male Volunteers
|
Phase 1 |